Navigation Links
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration (AMD).

The data, presented Monday by Alexander M. Eaton, M.D., at the Annual Meeting of the American Society of Retinal Specialists, also showed a trend for reduced GA lesion growth rates in patients receiving fenretinide. These data suggest that fenretinide may have an effect on both GA lesion size as well as the conversion to the more sight-threatening wet form of AMD. Fenretinide is the first oral therapeutic to complete a Phase 2 trial in GA patients.

"These results are very exciting as there are currently no drug therapies for geographic atrophy, and there are no treatments for the prevention of CNV," said Dr. Eaton, who was an investigator in the trial. "We are hopeful that the complete analysis will further validate these findings as fenretinide could slow vision loss in the millions of Americans who face blindness because of this disease."

The double-masked, placebo-controlled, multicenter, Phase 2b study evaluated 246 patients with GA. Patients were randomized into three cohorts and received once-daily doses of 100 mg or 300 mg of fenretinide or placebo for 24 months. Retinal lesion size was measured by color fundus photography, fundus autofluorescence and fluorescein angiography. Patients were also evaluated by contrast sensitivity, reading rate, visual acuity, optical coherence tomography, and the incidence of CNV.

Fenretinide was well tolerated with no severe drug-related adverse events and no significant effects on normal vision function.

At the conclusion of the two-year study, 15 of 82 patients (18.3 percent) in the placebo arm progressed to CNV, while 15 o
'/>"/>

SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
2. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
3. Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
4. Cord Blood America Says Debt Reduced $4.194 Million in 2009
5. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
6. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
7. The toxicity of antimicrobial silver in products can be reduced
8. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
9. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
10. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
11. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/27/2015)... TRIANGLE PARK, N.C. , Aug. 27, 2015 ... on the decision by FedEx, UPS and The ... of certain biological specimens classified as ,select agents, ... and long history of handling these sensitive shipments. ... knowledge of global transportation regulations, trained and certified ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Calif., Oct. 14 GenVault Corporation today,announces that ... Senior Vice,President of Business Development. Mr. Sutherland will ... for partnering,and licensing the company,s products and technologies ... Mr. Sutherland has more than 25 years ...
... Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer ... that its,distributor, Laszlo Meszaros of Kardia Hungary Kft., ... for Budapest, Hungary., (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ... at the new MeDoc HealthCare Center,(MDHC) located in ...
... chosen to enable patient care services in Australia through ... ... 110th Annual Convention --,Mirixa Corporation, the leader in pharmacy-based patient ... Australia, announced,today that they have signed a definitive technology licensing ...
Cached Biology Technology:Mark Sutherland Joins GenVault as Senior Vice President, Business Development 2Imaging Diagnostic Systems Sells Its CT Laser Mammography System to Budapest, Hungary 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... studied human brain samples to isolate a set of proteins ... shows an intriguing link between diseases and the evolution of ... of medical disability in the developed world according to the ... exceeds $300 billion. The brain is the most complex ...
... Federal Ministry of Education and Research (BMBF) will fund ... (FRM II) by German and international researchers to the ... years. The Helmholtz Research Centers Juelich, Berlin, and Geesthacht ... budgets. The basis for these grants is the cooperation ...
... It,s just a worm, a tiny soil-dwelling nematode worm ... biology as shown in a recent study authored by University ... on the circadian clock of the Caenorhabditis elegans ... Biology . "Circadian rhythms are important in all ...
Cached Biology News:The genetic basis of brain diseases 2The genetic basis of brain diseases 3German federal government bolsters neutron research in Garching 2German federal government bolsters neutron research in Garching 3Breakthrough in worm research has implications for human disease studies 2
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
... Standard Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
Biology Products: